Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market
NEW YORK, Oct. 13, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p0464105/Gout-Therapeutics-Market-to-2017--Entry-of-Novel-Therapies-such-as-Krystexxa-Uloric-Adenuric-and-Colcrys-to-Drive-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market
Summary
GBI Research has released its pharmaceutical research, "Gout Therapeutics Market to 2017 - Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market", which provides insights into gout therapeutics sales and price forecasts until 2017. The report also delves deep into global gout treatment usage patterns. Furthermore, the geographical distribution of the gout therapeutics market across key geographies (the US, the top five countries of Europe, and Japan) is also provided in the report. The report also provides insights into the gout therapeutics R&D pipeline and the promising future blockbusters by 2017. The report provides an in-depth analysis of acute and chronic gout. Furthermore, it also includes the market forecasts and treatment usage patterns of these four therapeutic indications. The report also covers the profiles of major biopharmaceutical companies in this therapeutics segment. Finally, analysis of mergers and acquisitions, and licensing agreements involving gout therapeutics, is also provided.
GBI Research analysis showed that the global gout therapeutics market was estimated at $542.6m in 2010, with a year-on-year growth rate of 7% between 2002 and 2010. The gout therapeutics market is expected to shift towards biologics that are more efficient and safe compared to conventional therapies. GBI Research forecasts the market to grow at a Compound Annual Growth Rate (CAGR) of approximately 16.3% between 2010 and 2017, to record a sales value of approximately $1,561.3m. The gout therapeutics market had only generics until the launch of Colcrys (colchicine) and TMX 67 (febuxostat) in 2009 and 2010 respectively. In-depth analysis of the report is based on proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of experts.
Scope
The report covers -
- Data and analysis on the gout therapeutics market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the gout therapeutics market from 2002 to 2010, with forecasts to 2017.
- In-depth analysis of the acute and chronic gout therapeutics market.
- Market data on geographical landscape and therapeutic landscape including market size, annual cost of therapy, revenues and treatment usage patterns such as diseased population, treatment seeking population, diagnosed population and prescription population.
- Key drivers and barriers that have created a significant impact on the market.
- Profiles of the major biopharmaceutical markets in the gout therapeutics segment. The key companies studied in this report are Takeda Pharmaceutical Company, Savient Pharmaceuticals, Novartis, Regeneron Pharmaceuticals and Teijin Pharma.
- Key M&A activities and Licensing Agreements, that have taken place between 2004 and 2010 in the gout therapeutics market.
Reasons to buy
The report will aid business development and marketing executives strategizing their product launches -
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
Table of Contents
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 7
2 Gout Therapeutics Market: Introduction 9
2.1 GBI Research Report Guidance 9
3 Gout Therapeutics Market: Market Overview 10
3.1 Introduction 10
3.1.1 Disease Overview 10
3.1.2 Global Market Overview 12
3.2 Revenue Forecasts for the Global Gout Therapeutics Market 12
3.2.1 Revenue 12
3.2.2 Annual Cost of Treatment (ACT) 14
3.2.3 Treatment Usage Patterns 15
4 Gout Therapeutics Market: Geographic Landscape 21
4.1 Revenue Analysis by Geography 21
4.2 The US 23
4.2.1 Revenue 23
4.2.2 Annual Cost of Treatment (ACT) 24
4.2.3 Treatment Usage Patterns 25
4.3 Top Five Countries of Europe 31
4.3.1 Revenue 31
4.3.2 Annual Cost of Treatment (ACT) 32
4.3.3 Treatment Usage Patterns 33
4.3.4 The UK 39
4.3.5 Germany 41
4.3.6 France 43
4.3.7 Italy 45
4.3.8 Spain 47
4.4 Japan 49
4.4.1 Revenue 49
4.4.2 Annual Cost of Treatment (ACT) 50
4.4.3 Treatment Usage Patterns 51
5 Gout Therapeutics Market: Therapeutic Landscape 57
5.1 Gout Therapeutics Market for Acute Gout 57
5.1.1 Introduction 57
5.1.2 Revenue 57
5.1.3 Revenue Analysis by Geography 59
5.1.4 Annual Cost of Treatment 61
5.1.5 Annual Cost of Treatment by Geography 62
5.1.6 Treatment Usage Patterns 64
5.2 Gout Therapeutics Market for Chronic Gout 70
5.2.1 Introduction 70
5.2.2 Revenue 70
5.2.3 Revenue Analysis by Geography 72
5.2.4 Annual Cost of Treatment 74
5.2.5 Annual Cost of Treatment by Geography 75
5.2.6 Treatment Usage Patterns 77
5.3 Drivers and Barriers to the Gout Therapeutics Market 83
5.3.1 Drivers to the Gout Therapeutics Market 83
5.3.2 Barriers to the Gout Therapeutics Market 84
6 Gout Therapeutics Market: Product Pipeline Analysis 85
6.1 Introduction 85
6.2 Research and Development Pipeline 85
6.2.1 Overview 85
6.2.2 Pipeline by Clinical Phases of Development 86
6.3 Profiles of Promising Drugs in the Gout Therapeutics Market 88
6.3.1 ACZ885 88
6.3.2 Arcalyst 88
7 Gout Therapeutics Market: Company Profiles 89
7.1 Takeda Pharmaceutical Company Limited 89
7.1.1 Company Overview 89
7.1.2 SWOT Analysis 89
7.2 Savient Pharmaceuticals, Inc. 90
7.2.1 Company Overview 90
7.2.2 SWOT Analysis 90
7.3 Novartis AG 91
7.3.1 Company Overview 91
7.3.2 SWOT Analysis 91
7.4 Regeneron Pharmaceuticals, Inc. 92
7.4.1 Company Overview 92
7.4.2 SWOT Analysis 92
7.5 Teijin Pharma Limited 93
7.5.1 Company Overview 93
7.5.2 SWOT Analysis 93
8 Gout Therapeutics Market: Strategic Consolidations 94
8.1 Overview 94
8.2 Mergers and Acquisitions 95
8.2.1 Major M&A Deals (2004-2010) 95
8.2.2 Deal Summary 96
8.2.3 Deals by Deal Value 97
8.2.4 Deals by Geography 98
8.2.5 Deals by Type 99
8.3 Licensing Agreements 100
8.3.1 Major Licensing Deals 100
8.3.2 Deal Summary 100
8.3.3 Deals by Geography 102
9 Gout Therapeutics Market: Appendix 103
9.1 Market Definitions 103
9.2 Abbreviations 103
9.3 Research Methodology 104
9.3.1 Coverage 104
9.3.2 Primary Research 105
9.3.3 Forecasts 105
9.3.4 Expert Panel Validation 108
9.4 Contact Us 108
9.5 Disclaimer 108
9.6 Sources 108
List of Tables
1.1 List of Tables
Table 1: Gout Therapeutics Market, Global, Revenue Forecasts, ($m), 2002-2010 13
Table 2: Gout Therapeutics Market, Global, Revenue Forecasts, ($m), 2010-2017 13
Table 3: Gout Therapeutics Market, Global, Annual Cost of Treatment, ($), 2002-2010 14
Table 4: Gout Therapeutics Market, Global, Annual Cost of Treatment, ($), 2010-2017 14
Table 5: Gout Therapeutics Market, Global Treatment Usage Patterns ('000), 2002-2010 15
Table 6: Gout Therapeutics Market, Global Treatment Usage Patterns ('000), 2010-2017 16
Table 7: Gout Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010 22
Table 8: Gout Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2017 22
Table 9: Gout Therapeutics Market, the US, Revenue Forecasts ($m), 2002-2010 23
Table 10: Gout Therapeutics Market, the US, Revenue Forecasts ($m), 2010-2017 23
Table 11: Gout Therapeutics Market, the US, Annual Cost of Treatment ($), 2002-2010 24
Table 12: Gout Therapeutics Market, the US, Annual Cost of Treatment ($), 2010-2017 24
Table 13: Gout Therapeutics Market, the US, Treatment Usage Patterns ('000), 2002-2010 25
Table 14: Gout Therapeutics Market, the US, Treatment Usage Patterns ('000), 2010-2017 26
Table 15: Gout Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2002-2010 31
Table 16: Gout Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2010-2017 31
Table 17: Gout Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2010 32
Table 18: Gout Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2010-2017 32
Table 19: Gout Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns ('000), 2002-2010 33
Table 20: Gout Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns ('000), 2010-2017 34
Table 21: Gout Therapeutics Market, the UK, Revenue Forecasts, ($m), 2002- 2010 39
Table 22: Gout Therapeutics Market, the UK, Revenue Forecasts, ($m), 2010- 2017 39
Table 23: Gout Therapeutics Market, the UK, Prescription Population ('000), 2002- 2010 40
Table 24: Gout Therapeutics Market, the UK, Prescription Population ('000), 2010- 2017 40
Table 25: Gout Therapeutics Market, Germany, Revenue Forecasts, ($m), 2002- 2010 41
Table 26: Gout Therapeutics Market, Germany, Revenue Forecasts, ($m), 2010- 2017 41
Table 27: Gout Therapeutics Market, Germany, Prescription Population ('000), 2002- 2010 42
Table 28: Gout Therapeutics Market, Germany, Prescription Population ('000), 2010- 2017 42
Table 29: Gout Therapeutics Market, France, Revenue Forecasts, ($m), 2002-2010 43
Table 30: Gout Therapeutics Market, France, Revenue Forecasts, ($m), 2010-2017 43
Table 31: Gout Therapeutics Market, France, Prescription Population ('000), 2002- 2010 44
Table 32: Gout Therapeutics Market, France, Prescription Population ('000), 2010- 2017 44
Table 33: Gout Therapeutics Market, Italy, Revenue Forecasts, ($m), 2002-2010 45
Table 34: Gout Therapeutics Market, Italy, Revenue Forecasts, ($m), 2010-2017 45
Table 35: Gout Therapeutics Market, Italy, Prescription Population ('000), 2002- 2017 46
Table 36: Gout Therapeutics Market, Italy, Prescription Population ('000), 2010- 2017 46
Table 37: Gout Therapeutics Market, Spain, Revenue Forecasts, ($m), 2002-2010 47
Table 38: Gout Therapeutics Market, Spain, Revenue Forecasts, ($m), 2010-2017 47
Table 39: Gout Therapeutics Market, Spain, Prescription Population ('000), 2002- 2010 48
Table 40: Gout Therapeutics Market, Spain, Prescription Population ('000), 2010- 2017 48
Table 41: Gout Therapeutics Market, Japan, Revenue Forecasts ($m), 2002-2010 49
Table 42: Gout Therapeutics Market, Japan, Revenue Forecasts ($m), 2010-2017 49
Table 43: Gout Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2010 50
Table 44: Gout Therapeutics Market, Japan, Annual Cost of Treatment ($), 2010-2017 50
Table 45: Gout Therapeutics Market, Japan, Treatment Usage Patterns ('000), 2002-2010 51
Table 46: Gout Therapeutics Market, Japan, Treatment Usage Patterns ('000), 2010-2017 52
Table 47: Gout Therapeutics Market, Acute Gout, Global Revenue Forecasts ($m), 2002-2010 58
Table 48: Gout Therapeutics Market, Acute Gout, Global Revenue Forecasts ($m), 2010-2017 58
Table 49: Gout Therapeutics Market, Acute Gout, Global Revenue Analysis by Geography ($m), 2002-2010 59
Table 50: Gout Therapeutics Market, Acute Gout, Global Revenue Analysis by Geography ($m), 2010-2017 60
Table 51: Gout Therapeutics Market, Acute Gout, Global Annual Cost of Treatment ($), 2002-2010 61
Table 52: Gout Therapeutics Market, Acute Gout, Global Annual Cost of Treatment ($), 2010-2017 61
Table 53: Gout Therapeutics Market, Acute Gout, Global Annual Cost of Treatment by Geography ($), 2002-2010 62
Table 54: Gout Therapeutics Market, Acute Gout, Global Annual Cost of Treatment by Geography ($), 2010-2017 63
Table 55: Gout Therapeutics Market, Acute Gout, Treatment Usage Patterns ('000), 2002-2010 64
Table 56: Gout Therapeutics Market, Acute Gout, Treatment Usage Patterns ('000), 2010-2017 65
Table 57: Gout Therapeutics Market, Chronic Gout, Global Revenue Forecasts ($m), 2002-2010 71
Table 58: Gout Therapeutics Market, Chronic Gout, Global Revenue Forecasts ($m), 2010-2017 71
Table 59: Gout Therapeutics Market, Chronic Gout, Global Revenue Analysis by Geography ($m), 2002-2010 72
Table 60: Gout Therapeutics Market, Chronic Gout, Global Revenue Analysis by Geography ($m), 2010-2017 73
Table 61: Gout Therapeutics Market, Chronic Gout, Global Annual Cost of Treatment ($), 2002-2010 74
Table 62: Gout Therapeutics Market, Chronic Gout, Global Annual Cost of Treatment ($), 2010-2017 74
Table 63: Gout Therapeutics Market, Chronic Gout, Global Annual Cost of Treatment by Geography ($), 2002-2010 75
Table 64: Gout Therapeutics Market, Chronic Gout, Global Annual Cost of Treatment by Geography ($), 2010-2017 76
Table 65: Gout Therapeutics Market, Chronic Gout, Global Treatment Usage Patterns ('000), 2002-2010 77
Table 66: Gout Therapeutics Market, Chronic Gout, Global Treatment Usage Patterns ('000), 2010-2017 78
Table 67: Gout Therapeutics Market, Global, Number of Discovery Molecules, 2010 86
Table 68: Gout Therapeutics Market, Global, Number of Preclinical Molecules, 2010 86
Table 69: Gout Therapeutics Market, Global, Number of IND Filed Molecules, 2010 86
Table 70: Gout Therapeutics Market, Global, Number of Phase I Molecules, 2010 86
Table 71: Gout Therapeutics Market, Global, Number of Phase II Molecules, 2010 87
Table 72: Gout Therapeutics Market, Global, Number of Phase III Molecules, 2010 87
Table 73: Gout Therapeutics Market, Global, Major M&A Deals, 2004-2010 95
Table 74: Gout Therapeutics Market, Global, Major Licensing Deals, 2005-2011 100
List of Figures
1.2 List of Figures
Figure 1: Gout Therapeutics Market, Global, Revenue Forecasts, ($m), 2002-2017 12
Figure 2: Gout Therapeutics Market, Global, Annual Cost of Treatment, ($), 2002-2017 14
Figure 3: Gout Therapeutics Market, Global Treatment Usage Patterns ('000), 2002-2017 15
Figure 4: Gout Therapeutics Market, Global, Diseased Population ('000), 2002-2017 17
Figure 5: Gout Therapeutics Market, Global, Treatment Seeking Population ('000) 18
Figure 6: Gout Therapeutics Market, Global, Diagnosed Population ('000) 19
Figure 7: Gout Therapeutics Market, Global, Prescription Population ('000) 20
Figure 8: Gout Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017 21
Figure 9: Gout Therapeutics Market, the US, Revenue Forecasts ($m), 2002-2017 23
Figure 10: Gout Therapeutics Market, the US, Annual Cost of Treatment ($), 2002-2017 24
Figure 11: Gout Therapeutics Market, the US, Treatment Usage Patterns ('000), 2002-2017 25
Figure 12: Gout Therapeutics Market, the US, Diseased Population ('000), 2002-2017 27
Figure 13: Gout Therapeutics Market, the US, Treatment Seeking Population ('000), 2002-2017 28
Figure 14: Gout Therapeutics Market, the US, Diagnosed Population ('000), 2002-2017 29
Figure 15: Gout Therapeutics Market, the US, Prescription Population ('000), 2002-2017 30
Figure 16: Gout Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2002-2017 31
Figure 17: Gout Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2017 32
Figure 18: Gout Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns ('000), 2002-2017 33
Figure 19: Gout Therapeutics Market, Top Five Countries of Europe, Diseased Population ('000), 2002-2017 35
Figure 20: Gout Therapeutics Market, Top Five Countries of Europe, Treatment Seeking Population ('000), 2002-2017 36
Figure 21: Gout Therapeutics Market, Top Five Countries of Europe, Diagnosed Population ('000), 2002-2017 37
Figure 22: Gout Therapeutics Market, Top Five Countries of Europe, Prescription Population ('000), 2002-2017 38
Figure 23: Gout Therapeutics Market, the UK, Revenue Forecasts, ($m), 2002-2017 39
Figure 24: Gout Therapeutics Market, the UK, Prescription Population ('000), 2002-2017 40
Figure 25: Gout Therapeutics Market, Germany, Revenue Forecasts, ($m), 2002-2017 41
Figure 26: Gout Therapeutics Market, Germany, Prescription Population ('000), 2002-2017 42
Figure 27: Gout Therapeutics Market, France, Revenue Forecasts, ($m), 2002-2017 43
Figure 28: Gout Therapeutics Market, France, Prescription Population ('000), 2002-2017 44
Figure 29: Gout Therapeutics Market, Italy, Revenue Forecasts, ($m), 2002-2017 45
Figure 30: Gout Therapeutics Market, Italy, Prescription Population ('000), 2002- 2017 46
Figure 31: Gout Therapeutics Market, Spain, Revenue Forecasts, ($m), 2002-2017 47
Figure 32: Gout Therapeutics Market, Spain, Prescription Population ('000), 2002-2017 48
Figure 33: Gout Therapeutics Market, Japan, Revenue Forecasts ($m), 2002-2017 49
Figure 34: Gout Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2017 50
Figure 35: Gout Therapeutics Market, Japan, Treatment Usage Patterns ('000), 2002-2017 51
Figure 36: Gout Therapeutics Market, Japan, Diseased Population ('000), 2002-2017 53
Figure 37: Gout Therapeutics Market, Japan, Treatment Seeking Population ('000), 2002-2017 54
Figure 38: Gout Therapeutics Market, Japan, Diagnosed Population ('000), 2002-2017 55
Figure 39: Gout Therapeutics Market, Japan, Prescription Population ('000), 2002-2017 56
Figure 40: Gout Therapeutics Market, Acute Gout, Global Revenue Forecasts ($m), 2002-2017 57
Figure 41: Gout Therapeutics Market, Acute Gout, Global Revenue Analysis by Geography ($m), 2002-2017 59
Figure 42: Gout Therapeutics Market, Acute Gout, Global Annual Cost of Treatment ($), 2002-2017 61
Figure 43: Gout Therapeutics Market, Acute Gout, Global Annual Cost of Treatment by Geography ($), 2002-2017 62
Figure 44: Gout Therapeutics Market, Acute Gout, Treatment Usage Patterns ('000), 2002-2017 64
Figure 45: Gout Therapeutics Market, Acute Gout, Diseased Population ('000), 2002-2017 66
Figure 46: Gout Therapeutics Market, Acute Gout, Treatment Seeking Population ('000), 2002-2017 67
Figure 47: Gout Therapeutics Market, Acute Gout, Diagnosed Population ('000), 2002-2017 68
Figure 48: Gout Therapeutics Market, Acute Gout, Prescription Population ('000), 2002-2017 69
Figure 49: Gout Therapeutics Market, Chronic Gout, Global Revenue Forecasts ($m), 2002-2017 70
Figure 50: Gout Therapeutics Market, Chronic Gout, Global Revenue Analysis by Geography ($m), 2002-2017 72
Figure 51: Gout Therapeutics Market, Chronic Gout, Global Annual Cost of Treatment ($), 2002-2017 74
Figure 52: Gout Therapeutics Market, Chronic Gout, Global Annual Cost of Treatment by Geography ($), 2002-2017 75
Figure 53: Gout Therapeutics Market, Chronic Gout, Global Treatment Usage Patterns ('000), 2002-2017 77
Figure 54: Gout Therapeutics Market, Chronic Gout, Global Diseased Population ('000), 2002-2017 79
Figure 55: Gout Therapeutics Market, Chronic Gout, Global Treatment Seeking Population ('000), 2002-2017 80
Figure 56: Gout Therapeutics Market, Chronic Gout, Global Diagnosed Population ('000), 2002-2017 81
Figure 57: Gout Therapeutics Market, Chronic Gout, Global Prescription Population ('000), 2002-2017 82
Figure 58: Gout Therapeutics Market, Global Drivers and Barriers, 2010-2017 84
Figure 59: Gout Therapeutics Market, Global, Number of Molecules by Phases (%), 2010 85
Figure 60: Gout Therapeutics Market, SWOT Analysis of Takeda Pharmaceutical Company Limited 89
Figure 61: Gout Therapeutics Market, SWOT Analysis of Savient Pharmaceuticals, Inc. 90
Figure 62: Gout Therapeutics Market, SWOT Analysis of Novartis AG 91
Figure 63: Gout Therapeutics Market, SWOT Analysis of Regeneron Pharmaceuticals, Inc. 92
Figure 64: Gout Therapeutics Market, SWOT Analysis of Teijin Pharma Limited 93
Figure 65: Gout Therapeutics Market, Global, Strategic Consolidations, (%), 2004-2010 94
Figure 66: Gout Therapeutics Market, Global, M&A Deals by Value, ($m) 2004-2010 97
Figure 67: Gout Therapeutics Market, Global, M&A Deals by Geography, 2004-2010 98
Figure 68: Gout Therapeutics Market, Global, M&A Deals by Type, 2004-2010 99
Figure 69: Gout Therapeutics Market, Global, Licensing Deals by Geography, 2005-2011 102
Figure 70: GBI Research Market Forecasting Model 107
To order this report:
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article